Results from a study called Mariposa found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced ...
The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle cell and beta thalassemia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback